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Abstract
Agmatine, an endogenous derivative of arginine, has been found to be effective in treating idiopathic pain, convulsion, stress-
mediated behavior, and attenuate the withdrawal symptoms of drugs like morphine. In the early stages of ischemic brain 
injury in animals, exogenous agmatine treatment was found to be neuroprotective. Agmatine is also considered as a putative 
neurotransmitter and is still an experimental drug. Chemically, agmatine is called agmatine 1-(4-aminobutyl guanidine). 
Crystallographic study data show that positively-charged guanidine can bind to the protein containing Gly and Asp residues, 
and the amino group can interact with the complimentary sites of Glu and Ser. In this study, we blocked the amino end of 
the agmatine by conjugating it with FITC, but the guanidine end was unchanged. We compared the neuroprotective function 
of the agmatine and agmatine-FITC by treating them in neurons after excitotoxic stimulation. We found that even the amino 
end blocked neuronal viability in the excitotoxic condition, by NMDA treatment for 1 h, was increased by agmatine-FITC, 
which was similar to that of agmatine. We also found that the agmatine-FITC treatment reduced the expression of nitric oxide 
production in NMDA-treated cells. This study suggests that even if the amino end of agmatine is blocked, it can perform its 
neuroprotective function.
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Introduction
Primary amine agmatine can be created naturally from 
α-amino l-arginine. The decarboxylation of l-arginine to 
produce agmatine occurs in the presence of the mammalian 
mitochondrial outer membrane enzyme arginine decarboxy-
lase. Agmatine is catabolized into prototypical polyamine 
putrescine by agmatinase, a human ureohydrolase. Agmatine 
has been found in different organs of the body at lower con-
centrations, with enrichments in a few parts of the brain 
and spinal cord, packaged in the synaptic vesicles [1–3]. n 
the synaptic vesicles, agmatine is found to be co-localized 
with other classical neurotransmitters such as glutamate and 
vasopressin and can be released by calcium-dependent depo-
larization [4, 5]. With the above characteristics, agmatine 
is believed to be a neuromodulator that can act as a neuro-
transmitter, and localized in the oxytocin and vasopressin 
neurons [6, 7].
Agmatine was found to be neuroprotective in different 
excitotoxic and ischemic neurological diseases. Agmatine 
has been reported to reduce vascular permeability in the 
brain; this induces gastric protection in ischemic-injury rats 
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[8]. The neuroprotective mechanism of agmatine is not yet 
clearly understood; however, it is believed that during the 
early hours of the ischemic/traumatic injury, activation of 
the unabated inducible nitric oxide synthase (iNOS) occurs, 
which increases nitric oxide (NO) production, whereas the 
level of arginine decarboxylase (ADC)/agmatine remains 
low [9–11]. In this condition, the sustained higher level 
of NO opens the N-methyl-d-aspartate (NMDA) channels 
through which the calcium influxes, causing neurotoxic-
ity. After several hours of injury, the ADC/agmatine level 
increases and controls the iNOS and NMDA receptor func-
tions [12, 13]. In addition to ischemic or traumatic injury, 
agmatine has been found to have a positive effect on neu-
rological diseases such as Alzheimer’s disease, Parkin-
son’s disease, epilepsy, and other mental diseases [14–16]. 
Agmatine was also reported to be anti-apoptotic, an effect it 
achieves by attenuating the expression of caspase-3 and Bax, 
and elevating the expression of BCL2, Nrf2, and PI3K. [15, 
17–20]. In a recent neurochemical profiling study, acute and 
sub-chronic oral treatment of agmatine was reported to be 
well tolerated and did not show any adverse effect in APP-
swe/PS1ΔE9 transgenic (Tg) mice, and also found to cross 
the blood brain barrier and accumulate in the brain [21].
Agmatine was first believed to be a clonidine-displac-
ing substance that specifically binds to α2-adrenoceptors, 
I1- and I2-binding sites [22]. However, later studies sug-
gested that agmatine can function through other neurological 
receptors, such as N-methyl-D-aspartate receptor, 2-amino-
3-(5-methyl-3-oxo-1,2-oxazol-4-yl) propanoic acid recep-
tor, kainate receptor, acetylcholine receptor, and serotonin 
receptor [23]. The positively-charged guanidine and amino 
end of the agmatine tend to bind with the Gly and Asp resi-
dues of the protein and the Glu and Ser residues of the com-
plementary sites of the protein, respectively [24]. These two 
ends in agmatine have been suggested to play a vital role in 
neuroprotection, but there is no specific report yet. In this 
study, we intended to visualize the exogenous agmatine by 
attaching a fluorescein isothiocyanate (FITC) to its amino 
end and studied the role of agmatine in in vitro neuron cul-
ture. Our goal was to check, if the modified fluorescence-
agmatine still conserve its neuroprotective function as the 




To a stirred solution of FITC (50 mg, 0.12 mmol) and TEA 
(18 μL, 0.12 mmol) in DMF (1 mL) was added agmatine 
(0.16 mg, 0.12 mmol) at room temperature. After stirring 
for 3 h at room temperature, the reaction was quenched 
by the addition of  H2O. The organic solution was washed 
with water and brine, dried over anhydrous  Na2SO4, fil-
tered, and concentrated under reduced pressure. The resi-
due was purified by flash column chromatography  (CH2Cl2: 
MeOH = 10:1) to give a product in 60% yield: 1H nuclear 
magnetic resonance (NMR) (400 MHz, DMSO-d6)δ.82 
(brs, 1 H), 8.24 (s, 1 H), 8.03 (brs, 1 H), 7.78 (d, 1 H, 
J = 9.3 Hz), 7.28 (brs, 2 H), 7.11 (d, 1 H, J = 9.3 Hz), 6.73 
(d, 2 H, J = 9.3 Hz), 6.52–6.48 (m, 4 H), 3.51–3.42 (m, 2 H), 
3.12–3.03 (m, 2 H), 1.61–1.45 (m, 4 H); ESI–MS calcd for 
 C26H25N5O5S  [M]+ 519.1 found 519.1.
Primary Neuronal Cell Culture
Primary neuron culture was done as previously reported 
[25]. Before primary neuronal cell culture, the plates were 
coated with Poly-d-Lysine (Gibco) containing laminin over-
night at room temperature, and the dishes were washed three 
times with autoclaved distilled water. Brains were extracted 
from ICR mice E14.5 (Koatech). The pregnant mice were 
euthanized using ether. Before incision, the abdomen was 
wiped with 70% ethanol to prevent possible contamina-
tion, after which the skin was cut and removed, and the 
abdominal wall was incised. Fetuses were decapitated with 
a pair of scissors, and the heads were placed in a petri dish 
containing hank’s balanced salt solution (HBSS). When 
the skull was opened, the olfactory bulbs, meninges, and 
hippocampus were removed systematically, and the cortex 
was isolated. The cells were pelleted by centrifugation at 
1000×g for 3 min, and the supernatant was removed. The 
cells were mechanically dissociated using a Pasteur pipette 
(20 times). Approximately 1 ×  106 cells/mL were plated on 
PDL-laminin-coated 6-well plates in a neurobasal medium 
(Gibco) containing l-glutamine (Hyclone), penicillin–strep-
tomycin (Hyclone), and B27 supplement (Gibco), and then 
cultured at 37 °C in 5% C02/95% air. After 7 days in vitro, 
the cells were treated with NMDA (50  μM), agmatine 
(100 μM), and agmatine-FITC (AgmF, 100 μM). To check 
the cellular uptake of the AgmF, cells were treated with 
AgmF and CellTracker™ Red CMTPX Dye (Thermo Fisher, 
cat: C34552). All animal experiments were conducted in 
accordance with the guidelines on the use and care of labo-
ratory animals established by the Animal Care Committee 
Yonsei University.
Immunocytochemistry
Neurons were washed three times with iced-PBS and per-
meabilized with 4% PFA. The cells were then incubated with 
primary antibodies at 4 °C overnight. The following primary 
antibodies were used: DCX (1:500), NOS2 (1:200). The pri-
mary antibody was then removed, and the cells were washed 
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three times for 3 min with PBST (10% with Trionx-100). 
The cells were incubated with FITC-conjugated anti-IgG 
(1:500) and rhodamine-conjugated anti-IgG (1:500) at room 
temperature for 2 h. After washing three times for 3 min 
with PBS, the cells were counterstained with DAPI (1:500) 
for 10 min at room temperature. They were imaged using 
a Zeiss LSM 700 confocal microscope (Carl Zeiss, Thorn-
wood, NY, USA). For each immunochemistry experiments 
3–5 independent experiments were performed and 4–5 
images from each experiment were analyzed while count-
ing the cell number.
Crystal Violet Staining
To check the viability of the adherent neurons after the 
NMDA and AgmF treatment we performed crystal violet 
staining of the neurons. After treating the cells with NMDA 
followed by Agmatine and AgmF we washed the cells with 
PBS for 2 times and stained the cells with crystal violet 
(0.5% in water/methanol 4/1) for 5 min and then rinsed with 
water and left to dry overnight [26]. The images were taken 
by using a light microscopy. Cell number was counted from 
4–5 images obtained from 4 independent experiments.
MTT Assay
Neurons (1 ×  106 cells/mL) were seeded in 24-well plates 
to monitor all experimental conditions. The cells were then 
treated with NMDA (50 μM) for 1 h followed by a PBS 
wash, agmatine, and AgmF for 6 h. Next, cells were rinsed 
twice with PBS, and the culture medium was replaced with 
neurobasal medium (Gibco). Then, 100 μL of 3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 
Sigma) solution (5 mg/mL in PBS) was added to each well. 
After 1 h of incubation, the medium was removed, and dime-
thyl sulfoxide was added to solubilize the purple formazan 
product of the MTT reaction. The supernatant from each 
well was analyzed using an enzyme-linked immunosorb-
ent assay plate reader at a wavelength of 570 nm, with 
background subtraction at 650 nm. All experiments were 
repeated at least three times. Cell viability in the control 
medium without any treatment was considered 100%. Cell 
viability was reported as the value relative to the control 
group.
Nitric Oxide Production in the Neurons
The neurons obtained from the ICR mice were cultured in 
a neurobasal medium (Gibco) containing 1% l-glutamine 
(Hyclone), 1% penicillin–streptomycin (Hyclone), and B27 
supplement (Gibco). The cells were plated at a density of 
1 × 106, pre-incubated for 24 h at 37 °C, and maintained in a 
humidified atmosphere containing 5%  CO2. The mammalian 
cells were treated with NMDA (50 μM) for 1 h and then 
washed 3 times with PBS to remove the NMDA and treated 
with agmatine and AgmF for 6 h in culture media. Accu-
mulated nitrite  (NO2−), as an index of nitric oxide (NO), in 
the media was determined using a colorimetric assay based 
on the Griess reaction. After 6 h cells were washed with 
PBS and fixed with 4% PFA and stored at 4 °C until NOS2 
staining.
Statistical Analysis
The data are quantified as the mean ± SEM from at least 
three different experiments performed from separate cell 
preparations, and at least quadruplicate determinations were 
performed in each experiment. Statistical tests to determine 
differences between groups others were analyzed with analy-
sis of variance followed by Tukey’s post hoc test. SigmaPlot 
12.0 (Systat Software Inc., San Jose, California, USA) for 
Windows was used. p values less than 0.05 were considered 
significant.
Results
Chemistry of Agmatine‑FITC and Neuronal Uptake
General
Analytical thin-layer chromatography was conducted on 
silica gel in 60 F254 glass plates. Compound spots were 
visualized by ultraviolet light (254 nm) and/or by stain-
ing with 10 wt% phosphomolybdic acid in ethanol. Flash 
column chromatography was performed using silica gel 60 
(230–400 mesh). NMR spectra were recorded on a Bruker 
DRX-400 instrument. Mass spectra were obtained using a 
Waters 3100 LC/MS System. Chemical reaction showing the 
making of agmatine-FITC (Fig. 1a). To confirm the cellular 
uptake of the AgmF, we treated the cultured neurons with 
AgmF (green) for 6 h, and then CellTracker™ Red CMTPX 
Dye (red) and confocal images were taken (Fig. 1b). Green 
AgmF was found in both the cell body and cell neurite.
AgmF can Protect the Neuronal Cells 
from NMDA‑Induced Neurotoxicity
NMDA receptors are found in the neuron cell body, and syn-
apses are responsible for important physiological and path-
ological conditions of neurons. Depending on the NMDA 
treatment concentration, NMDA receptors can regulate the 
intercellular response bi-directionally. Lower and higher 
NMDA concentrations in NMDA treatment can activate the 
survival and pro-death signaling in neurons [27]. To check 
the role of AmgF in cortical neurons, we treated the neurons 
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with a higher concentration of NMDA (50 µM) for 1 h, 
followed by AgmF (100 µM) for 6 h, and fixed cells were 
immunostained with the neuron marker DCX. We found that 
AgmF itself does not have any effect on neurons. Treatment 
with NMDA reduced the number of DCX-positive cells to 
31% as expected when compared with the control (100%). 
However, NMDA-treated cells, followed by AgmF, were 
approximately 37% higher than the NMDA-only treated 
group (Fig. 2a, b). The above results suggest that AgmF does 
not have any harmful effect on neurons and is neuroprotec-
tive in high NMDA treatment.
Comparison of the Neuroprotective Effects Between 
Agmatine and AgmF
The physiological function of endogenous agmatine is 
largely unknown. However, several studies have reported 
that exogenous agmatine treatment can reduce neuronal 
injury in both in vitro and in vivo disease models. With 
this view, we investigated the changes in neuroprotection 
by agmatine when the amino end is blocked, and only the 
guanidine end is active. In this investigation, NMDA-
treated cells were treated with agmatine and AgmF for 
6 h. Crystal violet staining of the fixed cells showed that 
agmatine (63% of the control) had a greater number of 
cells (about 41% more) than the NMDA (21% of control) 
(Fig. 3a, b). The AmgF (about 54% of the control) treat-
ment also has a significantly higher (about 33% more) 
number of cells than the NMDA-treated cells. However, 
the difference in the cell number between agmatine and 
AgmF was not significant, at approximately 8%. Again, 
in the MTT assay, the NMDA treatment reduced the cell 
viability to 54%, whereas NMDA treatment followed by 
agmatine and AgmF maintained the cell viability at 82% 
and 91%, respectively, compared to the control; this was 
significantly higher than that of the NMDA-only treat-
ment (Fig. 3c). The above results suggest that there was 
no significant difference in the neuroprotective functions 
of agmatine and AgmF.
AgmF Reduced no Production by Attenuating NOS2 
Expression
One of the mechanisms of neuroprotection by agmatine 
is the reduction of NO production. To investigate the 
involvement of this mechanism in AgmF-mediated neu-
roprotection, we performed the NO assay after treating 
the cells with NMDA, agmatine, and AgmF. NMDA treat-
ment increased NO production (1.3 μM) by about five-
fold compared to the control (0.3 μM). However, both 
agmatine and AgmF treatment significantly reduced NO 
production (0.7 and 0.6 μM) when compared with NMDA 
(Fig. 4a). Immune staining of the cells with NOS2 showed 
that NOS2 expression was increased by NMDA treatment; 
however, both agmatine and AgmF treatment followed by 
NMDA treatment significantly reduced NOS2 expression 
(Fig. 4b). The  NOS+ neurons are counted and found that 
NMDA has increased the NOS2 expressing cells about 
60% more than the control cells. However, the agmatine 
and the AgmF treatment have reduced the number of the 
 NOS+ about 50% of the NMDA treated cells (Fig. 4c). 
The above results show that AgmF exerts neuroprotective 
effects by reducing NO production, which is achieved by 
inhibiting NOS2 expression.
Fig. 1  Preparation of Agmatine-
FITC. a chemical reaction of 
FITC bind to the free amino 
end of Agm. b Cellular uptake 
of the AgmF was confirmed 
in primary cortical neurons by 
stained with cell tracker. Scale 
bar: 20 μm
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Discussion
In our study, we demonstrated the procedure of making a 
fluorescence agmatine by biding a FITC molecule at the 
amino end of the agmatine and the guanidine end remains 
active. After producing the fluorescence-agmatine we also 
evaluated that it protects against NMDA-mediated injury in 
neuronal cultures. Furthermore, even with the above modi-
fication of the agmatine structure, the quality of the neuro-
protective function remains unchanged.
Agmatine-expressing cells have been found in all regions 
of the brain, such as the hypothalamus, frontal cortex, stria-
tum, medulla, hippocampus, and locus coeruleus (LC), 
with measurable ADC activity [28]. However, the high-
est number of agmatine-expressing cells was found in the 
hypothalamus, which also had the highest ADC activity [28, 
29]. There are diverse mechanisms of neuroprotection in 
different neurodegenerative diseases by agmatine that have 
been reported by different research groups [16, 30, 31] and 
also by us. Agmatine belongs to the class of organic com-
pounds known as guanidines. Structurally, agmatine has two 
ends that consist of a guanidine moiety and an amino group 
[32]. In this study, we blocked the amino group by binding 
a FITC molecule and confirmed the binding of agmatine to 
FITC by NMR. The binding of FITC to the amino group did 
not change the neuronal uptake of agmatine. Although the 
actual function of endogenous agmatine has not yet been 
discovered, it is well known that exogenous agmatine can 
act as a neurotransmitter and protect neurons in different 
diseases such as AD, PD, ischemic stroke, traumatic brain 
injury, spinal cord injury, etc. [4, 14, 33–35]. In pathological 
conditions, increased extracellular glutamate over-activates 
the NMDARs, resulting in elevated  Ca2+ and  Na+ influx 
into the cell, which triggers NMDAR-mediated neuronal 
Fig. 2  Cellular damage 
protection by Agmatine-FITC 
(AgmF). DI7 cortical cells were 
treated with NMDA (50 µM 
for 1 h) followed by and AgmF 
(100 µM) for 6 h. a After 6 h, 
cortical cells showed healthy 
cell bodies with long neur-
ites. A The NMDA treatment 
showed that the number of 
cells with neurites gradually 
reduced with time. The a–d 
are the 4 × enlarged images of 
the corresponding white square 
boxed images. B The treat-
ment of AgmF with or without 
NMDA groups showed that the 
number of cells with neurites 
and cell bodies was signifi-
cantly higher than that in the 
NMDA-treated cells. Scale bar: 
50 μm. *P < 0.001 versus the 
NMDA, #p < 0.001 versus the 
cortical and $p < 0.01 versus 
NMDA + AgmF.
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excitotoxicity and causes neuronal cell death [36–38]. In 
our study, we found that NMDA treatment reduced the num-
ber of DCX-positive cells, but there was no change in the 
AgmF-treated cells. Moreover, AgmF inhibited the cytotoxic 
effect of NMDA. Therefore, even if the free amino end was 
blocked, agmatine would not be harmful to the neurons. 
Given that agmatine and AgmF might differ with respect to 
neuroprotection, we studied neuronal viability by agmatine 
and AgmF following NMDA treatment. The neuronal viabil-
ity by AgmF was found to be similar to that of agmatine.
NMDAR over-activation by exogenous NMDA treat-
ment produces NO by activating NOS, which is a major 
mediator of neuronal death [39–41]. As a result, controlling 
neuronal excitotoxicity and the inhibition of NO through 
Fig. 3  Neuroprotection by 
Agmatine (Agm) and AgmF. 
DIV7 cortical cells were treated 
with NMDA (50 µM) followed 
by Agm and AgmF (100 µM) 
for 6 h and then fixed and 
stained with crystal violet. a 
after 6 h, control cells showed 
healthy cell bodies with long 
neurites; however, NMDA 
showed a significantly lower 
number of cells with neurites, 
whereas the Agm and AgmF-
treated groups showed a healthy 
cell body with longer neurites 
compared to NMDA treatment. 
b Crystal violet-stained cells 
were counted. c MTT assay 
showed the same result as found 
in crystal violet staining. Scale 
bar: 50 μm. *P < 0.001 com-
pared to the control.
Fig. 4  AgmF reduces nitric oxide (NO) production via inhibition 
of NOS2 expression. a In the NMDA DIV7 cortical cells, NO pro-
duction was reduced after 6  h of treatment with Agm and AgmF. 
b NMDA-induced NOS2 expression was also reduced by Agm 
and AgmF treatment. c the  NOS2+ neurons are counted. Scale bar: 
50 μm. *P < 0.001 compared to the control.
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the modulation of NMDAR functions resulted in the prior 
choice of treatment for ion channel-related brain disorders. 
Primary amine agmatine has been reported to be a neuro-
protective agent by modulating the NMDAR, NO pathway, 
and oxidative stress in various neurodegenerative diseases 
[10, 39, 40]. In hypoxic microglia, agmatine attenuates 
NO production by inhibiting the expression of iNOS [41]. 
The endogenous neurotransmitter agmatine is a selective 
blocker of NMDAR [23, 40]. In our study, we found that 
both agmatine and AgmF treatment reduced the production 
of NO using NMDA by half, and there was no significant 
difference in NO production between them. The reduction 
of NO production was found to be mediated by the reduction 
of the activity of the enzyme NOS2. Several studies previ-
ously suggested that the reduction of NO production and 
NOS2 inhibition by agmatine was mediated through selec-
tive blockage of the NMDA subclass of glutamate receptors 
[42]. In our study, NO production and NOS2 inhibition by 
agmatine and AgmF were found to be similar, suggesting 
that there were no changes in the selective blockage of the 
NMDA subclass of glutamate receptors after blocking the 
free amino end of agmatine.
In conclusion, we suggest that the guanidine end of 
agmatine regulates its neuroprotective function. As of 
today, there is no agmatine conjugated with a fluorescent 
compound. Our modified FITC AgmF can be used in studies 
in which fluorescence agmatine is needed.
Supplementary Information The online version contains supplemen-
tary material available at https:// doi. org/ 10. 1007/ s11064- 021- 03319-9.
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